Suppr超能文献

1型强直性肌营养不良症原代人成肌细胞中的CTG重复序列检测

CTG-Repeat Detection in Primary Human Myoblasts of Myotonic Dystrophy Type 1.

作者信息

Hintze Stefan, Mensel Raphaela, Knaier Lisa, Schoser Benedikt, Meinke Peter

机构信息

Department of Neurology, LMU Klinikum, Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, Munich, Germany.

出版信息

Front Neurosci. 2021 Jun 28;15:686735. doi: 10.3389/fnins.2021.686735. eCollection 2021.

Abstract

Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder caused by unstable CTG-repeat expansions in the gene. Tissue mosaicism has been described for the length of these repeat expansions. The most obvious affected tissue is skeletal muscle, making it the first target for therapy development. To date there is no approved therapy despite some existing approaches. Thus, there is the demand to further advance therapeutic developments, which will in return require several well-characterized preclinical tools and model systems. Here we describe a modified method to identify the CTG-repeat length in primary human myoblasts isolated from DM1 patients that requires less genomic DNA and avoids radioactive labeling. Using this method, we show that primary human DM1 myoblast cultures represent a population of cells with different CTG-repeat length. Comparing DNA from the identical muscle biopsy specimen, the range of CTG-repeat length in the myoblast culture is within the same range of the muscle biopsy specimen. In conclusion, primary human DM1 myoblast cultures are a well-suited model to investigate certain aspects of the DM1 pathology. They are a useful platform to perform first-line investigations of preclinical therapies.

摘要

1型强直性肌营养不良症(DM1)是一种常染色体显性多系统疾病,由该基因中不稳定的CTG重复序列扩增引起。已经描述了这些重复序列扩增长度的组织镶嵌现象。受影响最明显的组织是骨骼肌,这使其成为治疗开发的首要目标。尽管有一些现有方法,但迄今为止尚无获批的治疗方法。因此,需要进一步推进治疗开发,而这反过来将需要几个特征明确的临床前工具和模型系统。在这里,我们描述了一种改进的方法,用于鉴定从DM1患者分离的原代人成肌细胞中的CTG重复序列长度,该方法所需的基因组DNA较少,并且避免了放射性标记。使用这种方法,我们表明原代人DM1成肌细胞培养物代表了一群具有不同CTG重复序列长度的细胞。比较来自相同肌肉活检标本的DNA,成肌细胞培养物中CTG重复序列长度的范围与肌肉活检标本的范围相同。总之,原代人DM1成肌细胞培养物是研究DM1病理学某些方面的合适模型。它们是进行临床前治疗一线研究的有用平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfbe/8274452/28c6079c19d6/fnins-15-686735-g001.jpg

相似文献

1
CTG-Repeat Detection in Primary Human Myoblasts of Myotonic Dystrophy Type 1.
Front Neurosci. 2021 Jun 28;15:686735. doi: 10.3389/fnins.2021.686735. eCollection 2021.
3
Inhibition of myogenesis in transgenic mice expressing the human DMPK 3'-UTR.
Hum Mol Genet. 2004 Mar 15;13(6):589-600. doi: 10.1093/hmg/ddh064. Epub 2004 Jan 20.
4
Nuclear Envelope Transmembrane Proteins in Myotonic Dystrophy Type 1.
Front Physiol. 2018 Oct 30;9:1532. doi: 10.3389/fphys.2018.01532. eCollection 2018.
5
Novel heat pulse extension-PCR-based method for detection of large CTG-repeat expansions in myotonic dystrophy type 1.
J Mol Diagn. 2013 Jan;15(1):110-5. doi: 10.1016/j.jmoldx.2012.07.004. Epub 2012 Nov 14.
8
Changes in myotonic dystrophy protein kinase levels and muscle development in congenital myotonic dystrophy.
Am J Pathol. 2003 Mar;162(3):1001-9. doi: 10.1016/s0002-9440(10)63894-1.
9
(CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
PLoS One. 2019 May 22;14(5):e0217317. doi: 10.1371/journal.pone.0217317. eCollection 2019.
10
Molecular and clinical characteristics of myotonic dystrophy type 1 in koreans.
Korean J Lab Med. 2008 Dec;28(6):483-92. doi: 10.3343/kjlm.2008.28.6.483.

引用本文的文献

1
Managing Myotonic Dystrophy Type 1 Complicated by Metabolic Syndrome.
JACC Case Rep. 2024 Dec 4;29(23):102761. doi: 10.1016/j.jaccas.2024.102761.

本文引用的文献

1
Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort.
Neurology. 2019 Sep 3;93(10):e995-e1009. doi: 10.1212/WNL.0000000000008056. Epub 2019 Aug 8.
5
Nuclear Envelope Transmembrane Proteins in Myotonic Dystrophy Type 1.
Front Physiol. 2018 Oct 30;9:1532. doi: 10.3389/fphys.2018.01532. eCollection 2018.
6
Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.
Neurotherapeutics. 2018 Oct;15(4):872-884. doi: 10.1007/s13311-018-00679-z.
7
Myotonic Dystrophy-A Progeroid Disease?
Front Neurol. 2018 Jul 25;9:601. doi: 10.3389/fneur.2018.00601. eCollection 2018.
8
Myotonic dystrophy type 1: clinical manifestations in children and adolescents.
Arch Dis Child. 2019 Jan;104(1):48-52. doi: 10.1136/archdischild-2018-314837. Epub 2018 Jun 5.
9
Core Clinical Phenotypes in Myotonic Dystrophies.
Front Neurol. 2018 May 2;9:303. doi: 10.3389/fneur.2018.00303. eCollection 2018.
10
Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle.
PLoS One. 2017 Sep 15;12(9):e0184987. doi: 10.1371/journal.pone.0184987. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验